Skip to main content

Verona Pharma plc

VRNADelisted Oct 7, 2025
Industry
Pharmaceutical Preparations
SEC CIK
0001657312

Verona Pharma plc was delisted on Oct 7, 2025; its insiders filed their last Form 4 on Oct 8, 2025; 243 institutions reported holding it in 13F filings for Q3 2025, worth $8.57B in total; superinvestors Duquesne Family Office and Soros Fund Management held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Verona Pharma plc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Verona Pharma plc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Verona Pharma plc
NameTitleLast reported holdingLast filingFilings, past year
Ebsworth David RDirector0IndirectOct 8, 20251
Shah MahendraDirector0Oct 8, 20251
Sinha VikasDirector0Oct 8, 20251
Hahn Mark WChief Financial Officer0Oct 8, 20251
Zaccardelli DavidPresident and CEO0Oct 8, 20251
Edwards MartinDirector0Oct 8, 20251
Ackermann ChristinaDirector0Oct 8, 20251
Ullman AndersDirector0Oct 8, 20251
Cunningham KennethDirector0Oct 8, 20251
Rickard Kathleen A.Chief Medical Officer0Oct 8, 20251
Deschamps LisaDirector0Oct 8, 20251
Brady James AloysiusDirector0Oct 8, 20251
Austwick MichaelDirector0Oct 8, 20251
Fisher AndrewGeneral Counsel0Oct 8, 20251
Poll ClaireGeneral Counsel1,176,920IndirectFeb 5, 20240
OrbiMed Advisors LLCDirector3,777,778IndirectMay 15, 20230
OrbiMed Capital GP VI LLCDirector3,777,778IndirectMay 15, 20230
Gupta RishiDirector3,777,778IndirectMay 15, 20230
Blavatnik Len10% Owner55,911,648IndirectAug 17, 20220
Access Industries Holdings LLC10% Owner55,911,648IndirectAug 17, 20220
Access Industries Management, LLC10% Owner55,911,648IndirectAug 17, 20220
AI Biotechnology LLC10% Owner55,911,648IndirectAug 17, 20220
Sinclair AndrewDirector–Aug 10, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 5, 2025 (view filing)Aug 14 daysCunningham KennethDirectorSSale−10.8K$13.14−$142.0K−11.9%79.8K after
Aug 5, 2025 (view filing)Aug 14 daysDeschamps LisaDirectorSSale−9.46K$13.14−$124.4K−10.0%84.9K after
Aug 5, 2025 (view filing)Aug 14 daysFisher AndrewGeneral CounselSSale−9.58K$13.14−$125.9K−2.2%417.9K after
Aug 5, 2025 (view filing)Aug 14 daysHahn Mark WChief Financial OfficerSSale−208.9K$13.14−$2.75M−1.6%12.5M after10b5-1
Aug 5, 2025 (view filing)Aug 14 daysRickard Kathleen A.Chief Medical OfficerSSale−58.3K$13.14−$766.5K−2.2%2.61M after10b5-1
Aug 5, 2025 (view filing)Aug 14 daysAckermann ChristinaDirectorSSale−1.81K$13.14−$23.8K−2.7%64.1K after
Aug 5, 2025 (view filing)Aug 14 daysAustwick MichaelDirectorSSale−11.3K$13.14−$148.3K−47.0%12.7K after
Aug 5, 2025 (view filing)Aug 14 daysBrady James AloysiusDirectorSSale−824$13.14−$10.8K−3.4%23.2K after
Aug 5, 2025 (view filing)Aug 14 daysZaccardelli DavidPresident and CEOSSale−208.9K$13.14−$2.75M−1.5%13.4M after10b5-1
Aug 5, 2025 (view filing)Aug 14 daysEbsworth David RDirectorSSale−1.90K$13.14−$25.0K−0.2%880.5K after
Aug 5, 2025 (view filing)Aug 14 daysEdwards MartinDirectorSSale−10.8K$13.14−$142.0K−6.4%158.0K after
Aug 5, 2025 (view filing)Aug 14 daysShah MahendraDirectorSSale−3.61K$13.14−$47.4K−3.7%93.5K after
Aug 5, 2025 (view filing)Aug 14 daysSinha VikasDirectorSSale−4.33K$13.14−$56.9K−4.4%94.1K after
Jun 18, 2025 (view filing)Jun 162 daysFisher AndrewGeneral CounselSSale−80.0K$11.53−$922.4K−18.2%360.0K after10b5-1
Jun 13, 2025 (view filing)Jun 112 daysHahn Mark WChief Financial OfficerSSale−400.0K$11.40−$4.56M−3.2%12.3M after10b5-1
Jun 13, 2025 (view filing)Jun 112 daysZaccardelli DavidPresident and CEOSSale−400.0K$11.40−$4.56M−2.9%13.2M after10b5-1
May 29, 2025 (view filing)May 27-292 daysHahn Mark WChief Financial OfficerSSale−400.0K$9.33−$3.73M−3.1%12.7M after3 lots10b5-1
May 29, 2025 (view filing)May 27-292 daysZaccardelli DavidPresident and CEOSSale−400.0K$9.33−$3.73M−2.9%13.6M after3 lots10b5-1
May 22, 2025 (view filing)May 202 daysSinha VikasDirectorSSale−160.0K$9.39−$1.50M−68.2%74.4K after10b5-1
May 22, 2025 (view filing)Apr 2923 daysSinha VikasDirectorSSale−160.0K$8.92−$1.43M−68.2%74.4K afterAmended2 lots10b5-1
May 16, 2025 (view filing)May 151 dayFisher AndrewGeneral CounselSSale−80.0K$8.57−$685.6K−18.2%360.0K afterAmended
May 16, 2025 (view filing)May 142 daysAckermann ChristinaDirectorSSale−40.0K$8.44−$337.6K−48.9%41.9K after10b5-1
May 8, 2025 (view filing)May 62 daysRickard Kathleen A.Chief Medical OfficerSSale−115.0K$8.82−$1.01M−4.3%2.55M after10b5-1
May 5, 2025 (view filing)May 14 daysRickard Kathleen A.Chief Medical OfficerSSale−49.2K$8.95−$440.3K−1.8%2.66M after2 lots10b5-1
May 5, 2025 (view filing)May 1-24 daysHahn Mark WChief Financial OfficerSSale−587.0K$9.05−$5.31M−4.3%13.1M after3 lots10b5-1
May 5, 2025 (view filing)May 1-24 daysZaccardelli DavidPresident and CEOSSale−587.0K$9.05−$5.31M−4.0%14.0M after3 lots10b5-1
May 1, 2025 (view filing)Apr 292 daysFisher AndrewGeneral CounselSSale−26.1K$8.98−$234.1K−6.8%360.0K after
May 1, 2025 (view filing)Apr 292 daysZaccardelli DavidPresident and CEOSSale−90.4K$8.98−$811.4K−0.6%14.4M after10b5-1
May 1, 2025 (view filing)Apr 292 daysRickard Kathleen A.Chief Medical OfficerSSale−34.4K$8.98−$308.8K−1.3%2.66M after10b5-1
May 1, 2025 (view filing)Apr 292 daysHahn Mark WChief Financial OfficerSSale−90.4K$8.98−$811.4K−0.7%13.5M after10b5-1
Mar 13, 2025 (view filing)Mar 121 dayRickard Kathleen A.Chief Medical OfficerSSale−79.3K$8.35−$661.9K−2.9%2.61M after10b5-1
Dec 6, 2024 (view filing)Dec 4-62 daysZaccardelli DavidPresident and CEOSSale−870.7K$5.01−$4.36M−5.8%14.2M after3 lots10b5-1
Dec 6, 2024 (view filing)Dec 4-62 daysHahn Mark WChief Financial OfficerSSale−882.0K$5.01−$4.42M−6.2%13.3M after3 lots10b5-1
Dec 2, 2024 (view filing)Nov 27-Dec 25 daysHahn Mark WChief Financial OfficerSSale−113.2K$5.01−$567.2K−0.8%14.2M after3 lots10b5-1
Dec 2, 2024 (view filing)Nov 27-Dec 25 daysZaccardelli DavidPresident and CEOSSale−125.3K$5.01−$627.6K−0.8%15.1M after3 lots10b5-1
Nov 26, 2024 (view filing)Nov 25-261 dayHahn Mark WChief Financial OfficerSSale−2.40K$5.00−$12.0K0.0%14.3M after2 lots10b5-1
Nov 26, 2024 (view filing)Nov 251 dayZaccardelli DavidPresident and CEOSSale−1.60K$5.00−$8.00K0.0%15.2M after10b5-1
Nov 26, 2024 (view filing)Nov 251 dayRickard Kathleen A.Chief Medical OfficerSSale−240.0K$4.90−$1.18M−8.2%2.67M after10b5-1
Nov 18, 2024 (view filing)Nov 18Same dayEbsworth David RDirectorPPurchase+20.0K$4.44+$88.8K+2.2%940.0K after
Nov 13, 2024 (view filing)Nov 112 daysZaccardelli DavidPresident and CEOSSale−2.40K$5.00−$12.0K0.0%15.2M after10b5-1
Nov 13, 2024 (view filing)Nov 112 daysHahn Mark WChief Financial OfficerSSale−2.40K$5.00−$12.0K0.0%14.3M after10b5-1
Nov 7, 2024 (view filing)Nov 61 dayEbsworth David RDirectorPPurchase+39.4K$4.80+$188.9K+4.5%920.0K after
Nov 7, 2024 (view filing)Nov 61 dayAckermann ChristinaDirectorPPurchase+41.9K$4.74+$198.5KNew position41.9K after
Nov 5, 2024 (view filing)Nov 1-44 daysZaccardelli DavidPresident and CEOSSale−141.0K$4.39−$618.7K−0.9%15.2M after2 lots10b5-1
Nov 5, 2024 (view filing)Nov 1-44 daysHahn Mark WChief Financial OfficerSSale−129.7K$4.39−$568.8K−0.9%14.3M after2 lots10b5-1
Oct 25, 2024 (view filing)Oct 24-251 dayHahn Mark WChief Financial OfficerSSale−144.6K$4.38−$633.2K−1.0%13.7M after2 lots10b5-1
Oct 25, 2024 (view filing)Oct 23-252 daysZaccardelli DavidPresident and CEOSSale−144.8K$4.38−$634.3K−1.0%14.6M after3 lots10b5-1
Oct 22, 2024 (view filing)Oct 18-224 daysZaccardelli DavidPresident and CEOSSale−514.2K$4.38−$2.25M−3.4%14.7M after3 lots10b5-1
Oct 22, 2024 (view filing)Oct 18-224 daysHahn Mark WChief Financial OfficerSSale−525.8K$4.38−$2.30M−3.7%13.8M after3 lots10b5-1
Sep 13, 2024 (view filing)Sep 112 daysZaccardelli DavidPresident and CEOSSale−600.0K$3.76−$2.26M−3.8%15.3M after10b5-1